OMB APPROVAL

OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 10.4 -----

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 1) *

RIGEL PHARMACEUTICALS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
766559603
(CUSIP Number)
DECEMBER 31, 2007
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act out shall be subject to all other provisions of the Act (however, see the Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.
CUSIP No. 766559603 13G/A Page 2 of 10 Pages
. NAMES OF REPORTING PERSONS

Great Point Partners, LLC

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

37-1475292

2.	CHECK THE A	PPROPRIATE B	OX IF A MEMBER OF A GROUP						
	(a) []							
	(b) []							
 3.	SEC USE ONL								
	CITIZENSHIP		ORGANIZATION						
•	USA	OK TEMOE OF	OROMINITION						
NUMBER	OF SHARES	5.	SOLE VOTING POWER						
	FICIALLY BY EACH	6.	SHARED VOTING POWER						
EPORTING PERSON WITH		7.	SOLE DISPOSITIVE POWER	656 , 900					
		8.	SHARED DISPOSITIVE POW	ER 656,900					
9.	AGGREGATE A	MOUNT BENEFI	CIALLY OWNED BY EACH REPOR	TING PERSON					
	65	6,900							
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)								
11.	PERCENT OF	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)							
	2.	12%							
L2.	TYPE OF REP	TYPE OF REPORTING PERSON (See Instructions)							
	00								
	 No. 766559603	-	13G/A	Page 3 of 10 Pages					
		_							
l.	NAMES OF RE	NAMES OF REPORTING PERSONS							
	Dr. Jeffrey	R. Jay, M.D							
	I.R.S. IDEN	TIFICATION N	O. OF ABOVE PERSON (ENTITI	ES ONLY):					
2.	CHECK THE A	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
	(a) []							
	(b) []							
 3.	SEC USE ONL								
 4.			ORGANIZATION						
-	USA	3_ 32							
NUMBER	OF SHARES	5.	SOLE VOTING POWER						
BENE	FICIALLY BY EACH	6.		0					
REPORTI	ING PERSON WITH	7.		656,900					
V	A T T II			0					
		8.	SHARED DISPOSITIVE POW	ER 656,900					
9.	AGGREGATE A	MOUNT BENEFI	CIALLY OWNED BY EACH REPOR	TING PERSON					
	65	6,900							
10.		F THE AGGREG	ATE AMOUNT IN ROW (9) EXCL s)	UDES CERTAIN					

11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)									
		2.12%								
12. TYPE OF REPORTING PERSON (See Instructions)										
	IN									
	. 7665596			13G/A		Page 4 of 10 Pages				
1.	NAMES OF REPORTING PERSONS									
	Mr. David Kroin									
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):									
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP									
	(a) []									
	(b)	[]								
3.	SEC USE	ONLY								
4.	CITIZENS	CITIZENSHIP OR PLACE OF ORGANIZATION								
	USA									
NUMBER O			5.	SOLE VOTIN	IG POWER					
BENEFICOWNED B			6.	SHARED VOT	'ING POWER	0				
REPORTING WI			7.	SOLE DISPO	SITIVE POWER	656,900				
			8.	SHARED DIS	POSITIVE POWE	0 R				
						656,900				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON									
	656,900									
10.		X IF THE A See Instru		AMOUNT IN	ROW (9) EXCLU	DES CERTAIN				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)									
		2.12%								
12.	TYPE OF	REPORTING	PERSON (S	See Instruc	tions)					
		IN								
	. 7665596			13G/A		Page 5 of 10 Pages				
ITEM 1.										
	(a)	Name of Issuer								
		Rigel Pharmaceuticals, Inc.								
	(b)	Address of Issuer's Principal Executive Offices								
			erans Blvd	l. co, CA 940	182					
ITEM 2.		Doucii Sal	. rrancisc	.o, on 940	.02					
TIBN Z.	(2)	Namo of 1	Dorson Eil	ing						
	(a)	Name OI h	Person Fil	.1119						

Great Point Partners, LLC

Dr. Jeffrey M. Jay, M.D. Mr. David Kroin

The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2008, a copy of which is filed with this Schedule 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) (1) under the Act.

(b) Address of Principal Business Office, or if none, Residence

The address of the principal business office of each of the Reporting Persons is

165 Mason Street, 3rd Floor Greenwich, CT 06830

(c) Citizenship

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey M. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

766559603

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(b) OR 240.13D.2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

Not Applicable.

- (a) [] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780)
- (b) [] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) [] Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).

CUSIP No. 766559603 13G/A Page 6 of 10 Pages

- (d) [] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) [] An investment adviser in accordance with ss.240.13d-1 (b) (1) (ii) (E).
- (f) [] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F).
- (g) [] A parent holding company or control person in accordance with $ss.240.13d-1\,(b)\,(1)\,(ii)\,(G)\,.$
- (h) [] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) [] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) [] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP

Great Point Partners, LLC ("Great Point") is the investment manager of Biomedical Value Fund, L.P. ("BVF"), and by virtue of such status may be deemed to be the beneficial owner of the 354,724 shares of Common Stock of the Issuer owned by BVF (the "BVF Shares"). Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Great Point is the investment manager of Biomedical Offshore Value Fund, Ltd. ("BOVF"), and by virtue of such status may be deemed to be the beneficial owner of the 302,176 shares of Common Stock of the Issuer owned by BOVF (the "BOVF Shares"). Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Each of Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interest.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item $\scriptstyle 1$

- 1. GREAT POINT PARTNERS, LLC
- (a) Amount beneficially owned: 656,900
- (b) Percent of class: 2.12%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 0 -
 - (ii) Shared power to vote or to direct the vote: 656,900

CUSIP No. 766559603 13G/A Page 7 of 10 Pages

- (iii) Sole power to dispose or to direct the disposition
- (iv) Shared power to dispose or to direct the disposition of: 656.900
- 2. DR. JEFFREY R. JAY, M.D.
- (a) Amount beneficially owned: 656,900
- (b) Percent of class: 2.12%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 0
 - (ii) Shared power to vote or to direct the vote: 656,900
 - (iii) Sole power to dispose or to direct the disposition of: $\mathbf{0}$
 - (iv) Shared power to dispose or to direct the disposition of: 656,900
- 3. MR. DAVID KROIN
- (a) Amount beneficially owned: 656,900
- (b) Percent of class: 2.12%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 0
 - (ii) Shared power to vote or to direct the vote: 656,900
 - (iii) Sole power to dispose or to direct the disposition of: 0 $\,$
 - (iv) Shared power to dispose or to direct the disposition of: 656,900

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

See item 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not Applicable.

Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

CUSIP No. 766559603 13G/A Page 8 of 10 Pages

Not Applicable.

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

CUSIP No. 766559603 13G/A Page 9 of 10 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2008

GREAT POINT PARTNERS, LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.

Dr. Jeffrey R. Jay, M.D.,

as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.

DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin

MR. DAVID KROIN

EXHIBIT A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G/A

The undersigned hereby agree as follows:

- (i) Each of them is individually eligible to use the Schedule 13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on behalf of each of them; and
- (ii) Each of them is responsible for the timely filing of such Schedule 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: February 14, 2008

Dr. Jeffrey R. Jay, M.D.,
as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.

DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin

MR. DAVID KROIN

By: /s/ Dr. Jeffrey R. Jay, M.D.